Search - tctmd.com

Displaying 1 - 20 of 201

Sort: Relevancy | Date

News Conference News TCT 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

Caitlin E. Cox

November 04, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Dimitrios Karmpaliotis, Master Operator and Mentor With ‘Heart of Gold,’ Dies at 53

Yael L. Maxwell

June 09, 2025

News Conference News EuroPCR 2025

Myval Noninferior to Other THVs at 1 Year, but Questions Persist

L.A. McKeown

May 21, 2025

News Conference News EuroPCR 2025

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

Yael L. Maxwell

May 21, 2025

News Features

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Yael L. Maxwell

March 27, 2025

News Industry News

Pi-Cardia Receives FDA Market Clearance for ShortCut™

October 01, 2024

News Conference News NY Valves 2024

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

Michael O'Riordan

June 11, 2024

News Conference News EuroPCR 2024

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

Michael O'Riordan

May 15, 2024

News Conference News EuroPCR 2024

Myval Matches Contemporary TAVI at 30 Days, but Do More Sizes Matter?

Shelley Wood

May 15, 2024

News Industry News

Concept Medical Announces Enrollment of First Patient in “Magical-ISR” IDE Study in the US

April 19, 2024

News Opinion Off Script

Passion, Persistence, and Generosity: Remembering Alain Cribier

Martin B. Leon, MD

February 27, 2024

News Daily News

Alain Cribier’s Death Mourned, His Legacy Celebrated Around the World

Shelley Wood

February 19, 2024

News Conference News PCR London Valves 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Shelley Wood

November 27, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

L.A. McKeown

November 11, 2023

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Conference News TVT 2023

Solid Anchoring, Good Echo Results With Transapical TMVR at 2 Years

Michael O'Riordan

June 09, 2023

Advertisement

What Makes MedTech Great—or Not—and Envisioning Its Future

What’s Going to Be Hot at TCT 2025

Dimitrios Karmpaliotis, Master Operator and Mentor With ‘Heart of Gold,’ Dies at 53

Myval Noninferior to Other THVs at 1 Year, but Questions Persist

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Pi-Cardia Receives FDA Market Clearance for ShortCut™

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

Myval Matches Contemporary TAVI at 30 Days, but Do More Sizes Matter?

Concept Medical Announces Enrollment of First Patient in “Magical-ISR” IDE Study in the US

Passion, Persistence, and Generosity: Remembering Alain Cribier

Alain Cribier’s Death Mourned, His Legacy Celebrated Around the World

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Solid Anchoring, Good Echo Results With Transapical TMVR at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content